162 related articles for article (PubMed ID: 37725114)
1. The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
Jabloñski M; Rodríguez MS; Rivero EM; Bruque CD; Vanzulli S; Bruzzone A; Pérez Piñero C; Lüthy IA
Cancer Chemother Pharmacol; 2023 Dec; 92(6):485-499. PubMed ID: 37725114
[TBL] [Abstract][Full Text] [Related]
2. The β 2-Adrenergic Agonist Salbutamol Inhibits Migration, Invasion and Metastasis of the Human Breast Cancer MDA-MB- 231 Cell Line.
Rivero EM; Piñero CP; Gargiulo L; Entschladen F; Zänker K; Bruzzone A; Lüthy IA
Curr Cancer Drug Targets; 2017; 17(8):756-766. PubMed ID: 28359245
[TBL] [Abstract][Full Text] [Related]
3. Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.
Pérez Piñero C; Bruzzone A; Sarappa MG; Castillo LF; Lüthy IA
Br J Pharmacol; 2012 May; 166(2):721-36. PubMed ID: 22122228
[TBL] [Abstract][Full Text] [Related]
4. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.
Liang Y; Wu G; Luo T; Xie H; Zuo Q; Huang P; Li H; Chen L; Lu H; Chen Q
Drug Des Devel Ther; 2023; 17():129-142. PubMed ID: 36712945
[TBL] [Abstract][Full Text] [Related]
5. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Choy C; Raytis JL; Smith DD; Duenas M; Neman J; Jandial R; Lew MW
Oncol Rep; 2016 Jun; 35(6):3135-42. PubMed ID: 27035124
[TBL] [Abstract][Full Text] [Related]
8. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
9. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Pasquier E; Ciccolini J; Carre M; Giacometti S; Fanciullino R; Pouchy C; Montero MP; Serdjebi C; Kavallaris M; André N
Oncotarget; 2011 Oct; 2(10):797-809. PubMed ID: 22006582
[TBL] [Abstract][Full Text] [Related]
10. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
11. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Español AJ; Salem A; Di Bari M; Cristofaro I; Sanchez Y; Tata AM; Sales ME
PLoS One; 2020; 15(9):e0226450. PubMed ID: 32911509
[TBL] [Abstract][Full Text] [Related]
12. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
13. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
Amith SR; Wilkinson JM; Baksh S; Fliegel L
Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
[TBL] [Abstract][Full Text] [Related]
14. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
15. Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells.
Sezer G; Caner A; Önal MG; Cumaoğlu A
Indian J Med Res; 2022 Jul; 156(1):70-76. PubMed ID: 36510900
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
17. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
18. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
19. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
[TBL] [Abstract][Full Text] [Related]
20. Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
Hedayat M; Khezri MR; Jafari R; Malekinejad H; Majidi Zolbanin N
Med Oncol; 2023 Aug; 40(9):263. PubMed ID: 37548777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
